GENEVIEVE ALLOU: Open Payments
NPI 1942836960 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,981 in 90 payments from 16 companies in 2025. Trend: 2023 $2,819 · 2024 $3,271 · 2025 $1,981
Food & beverage: $1,981
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $442 |
| Madrigal Pharmaceuticals | 11 | $312 |
| Gilead Sciences, Inc. | 10 | $270 |
| Ardelyx, Inc. | 7 | $238 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $214 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $168 |
| GENZYME CORPORATION | 4 | $115 |
| Intercept Pharmaceuticals, Inc. | 3 | $52 |
| Janssen Biotech, Inc. | 2 | $35 |
| Boston Scientific Corporation | 1 | $24 |
Products named: REZDIFFRA, IBSRELA, XIFAXAN, LINZESS, RINVOQ, DUPIXENT, ENTYVIO, MAVYRET.
Industry payments across NE — which companies pay providers there.
